Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007, Article ID 23513, 7 pages
http://dx.doi.org/10.1155/2007/23513
Review Article

Cannabinoids: A New Group of Agonists of PPARs

School of Biomedical Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK

Received 30 April 2007; Accepted 13 September 2007

Academic Editor: J. Vanden Heuvel

Copyright © 2007 Yan Sun and Andy Bennett. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Mechoulam and Y. Gaoni, “Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids,” Tetrahedron, vol. 21, no. 5, pp. 1223–1229, 1965. View at Publisher · View at Google Scholar
  2. A. C. Howlett, “Pharmacology of cannabinoid receptors,” Annual Review of Pharmacology Toxicology, vol. 35, pp. 607–634, 1995.
  3. R. Mechoulam, E. Fride, and V. Di Marzo, “Endocannabinoids,” European Journal of Pharmacology, vol. 359, no. 1, pp. 1–18, 1998. View at Publisher · View at Google Scholar
  4. S. A. Cook, J. A. Lowe, and B. R. Martin, “CB1 receptor antagonist precipitates withdrawal in mice exposed to Δ9- tetrahydrocannabinol,” Journal of Pharmacology and Experimental Therapeutics, vol. 285, no. 3, pp. 1150–1156, 1998.
  5. T. Nadulski, F. Pragst, and G. Weinberg et al., “Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of thc verses standardized cannabis extract,” Therapeutic Drug Monitoring, vol. 27, no. 6, pp. 799–810, 2005. View at Publisher · View at Google Scholar
  6. R. G. Pertwee, “Pharmacology of cannabinoid CB1 and CB2 receptors,” Pharmacology and Therapeutic, vol. 74, pp. 129–180, 1997.
  7. B. R. Martin, D. R. Compton, and B. F. Thomas et al., “Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs,” Pharmacology Biochemistry and Behavior, vol. 40, no. 3, pp. 471–478, 1991. View at Publisher · View at Google Scholar
  8. W. A. Devane, A. Breuer, T. Sheskin, T. U. C. Jarbe, M. S. Eisen, and R. Mechoulam, “A novel probe for the cannabinoid receptor,” Journal of Medicinal Chemistry, vol. 35, no. 11, pp. 2065–2069, 1992.
  9. D. M. Lambert and C. J. Fowler, “The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications,” Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5059–5087, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. K.-O. Jonsson, S. Vandevoorde, D. M. Lambert, G. Tiger, and C. J. Fowler, “Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide,” British Journal of Pharmacology, vol. 133, no. 8, pp. 1263–1275, 2001.
  11. A. C. Howlett, F. Barth, and T. I. Bonner et al., “International union of pharmacology. XXVII. Classification of cannabinoid receptors,” Pharmacological Reviews, vol. 54, no. 2, pp. 161–202, 2002. View at Publisher · View at Google Scholar
  12. J. L. Wiley and B. R. Martin, “Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes,” Chemistry and Physics of Lipids, vol. 121, no. 1-2, pp. 57–63, 2002.
  13. D. Smart and J. C. Jerman, “Anandamide: an endogenous activator of the vanilloid receptor,” Trends in Pharmacological Sciences, vol. 21, no. 4, p. 134, 2000. View at Publisher · View at Google Scholar
  14. A. Calignano, R. G. La, and D. Piomelli, “Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide,” European Journal of Pharmacology, vol. 419, no. 2-3, pp. 191–198, 2001. View at Publisher · View at Google Scholar
  15. V. Di Marzo, C. S. Breivogel, and Q. Tao et al., “Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain,” Neurochemical Research, vol. 75, no. 6, pp. 2434–2444, 2000.
  16. C. S. Breivogel, G. Griffin, V. Di Marzo, B. R. Martin, R. K. Razdan, A. M. Zimmer, A. Zimmer, and B. R. Martin, “Evidence for a new G protein-coupled cannabinoid receptor in mouse brain,” Molecular Pharmacology, vol. 60, no. 1, pp. 155–163, 2001.
  17. E. B. Russo, A. Burnett, B. Hall, and K. K. Parker, “Agonistic properties of cannabidiol at 5-HT1a receptors,” Neurochemical Research, vol. 30, no. 8, pp. 1037–1043, 2005. View at Publisher · View at Google Scholar · View at PubMed
  18. S. S. Davies, A. V. Pontsler, and G. K. Marathe et al., “Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor γ ligands and agonists,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16015–16023, 2001. View at Publisher · View at Google Scholar · View at PubMed
  19. M. Gottlicher, E. Widmark, Q. Li, and J.-A. Gustafsson, “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653–4657, 1992. View at Publisher · View at Google Scholar
  20. K. Yu, W. Bayona, and C. B. Kallen et al., “Differential activation of peroxisome proliferator-activated receptors by eicosanoids,” Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983, 1995. View at Publisher · View at Google Scholar
  21. M. V. Chakravarthy, Z. Pan, and Y. Zhu et al., ““New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis,” Cell Metabolism, vol. 1, no. 5, pp. 309–322, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar
  23. T. M. Willson, J. E. Cobb, and D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones,” Journal Medical Chemistry, vol. 39, pp. 665–668, 1996.
  24. W. R. Oliver Jr., J. L. Shenk, and M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, pp. 5306–5311, 2001.
  25. J. Fu, F. Oveisi, S. Gaetani, E. Lin, and D. Piomelli, “Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats,” Neuropharmacology, vol. 48, no. 8 SPEC. ISS., pp. 1147–1153, 2005. View at Publisher · View at Google Scholar · View at PubMed
  26. J. Fu, S. Gaetani, and F. Oveisi et al., “Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α,” Nature, vol. 425, no. 6953, pp. 90–93, 2003.
  27. M. Guzmàn, V. J. Lo, J. Fu, F. Oveisi, C. Blàzquez, and D. Piomelli, “Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α),” Journal of Biological Chemistry, vol. 279, no. 27, pp. 27849–27854, 2004.
  28. S. E. O'Sullivan, E. J. Tarling, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma,” Biochemical and Biophysical Research Communications, vol. 337, no. 3, pp. 824–831, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. R. B. Zurier, R. G. Rossetti, J. H. Lane, J. M. Goldberg, S. A. Hunter, and S. H. Burstein et al., “Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure,” Arthritis and Rheumatism, vol. 41, no. 1, pp. 163–170, 1998. View at Publisher · View at Google Scholar
  30. J. Liu, H. Li, S. H. Burstein, R. B. Zurier, and J. D. Chen, “Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid,” Molecular Pharmacology, vol. 63, pp. 983–992, 2003.
  31. F. Maingret, A. J. Patel, M. Lazdunski, and E. Honorè, “The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1,” EMBO Journal, vol. 20, no. 1-2, pp. 47–54, 2001. View at Publisher · View at Google Scholar · View at PubMed
  32. V. Di Marzo, A. Fontana, and H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandanide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994.
  33. C. J. Fowler, G. Tiger, A. Ligresti, M. L. Lòpez-Rodrìguez, and V. Di Marzo, “Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle,” European Journal of Pharmacology, vol. 492, no. 1, pp. 1–11, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. V. Di Marzo, T. Bisogno, P. L. De, D. Melck, and B. R. Martin, “Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids,” Current Medicinal Chemistry, vol. 6, no. 8, pp. 721–744, 1999.
  35. S. H. Burstein, R. G. Rossetti, B. Yagen, and R. B. Zurier, “Oxidative metabolism of anandamide,” Prostaglandins and Other Lipid Mediators, vol. 61, no. 1-2, pp. 29–41, 2000. View at Publisher · View at Google Scholar
  36. M. Bouaboula, S. Hilairet, J. Marchand, L. Fajas, G. Le Fur, and P. Casellas, “Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation,” European Journal of Pharmacology, vol. 517, no. 3, pp. 174–181, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. Y. Sun, S. P. H. Alexander, D. A. Kendall, and A. J. Bennett, “Cannabinoids and PPARα signalling,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1095–1097, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. V. J. Lo, J. Fu, and G. Astarita et al., “The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide,” Molecular Pharmacology, vol. 67, no. 1, pp. 15–19, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski, “Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2,” Molecular Pharmacology, vol. 70, no. 1, pp. 101–111, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. S. Vandevoorde and D. M. Lambert, “Focus on the three key enzymes hydrolysing endocannabinnoids as new drug targets,” Current Pharmaceutical Design, vol. 11, no. 20, pp. 2647–2668, 2005. View at Publisher · View at Google Scholar
  41. N. Ueda, K. Yamanaka, and S. Yamamoto, “Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35552–35557, 2001. View at Publisher · View at Google Scholar · View at PubMed
  42. J. Lengqvist, U. A. Mata De, and A.-C. Bergman et al., “Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor α ligand-binding domain,” Molecular and Cellular Proteomics, vol. 3, no. 7, pp. 692–703, 2004.
  43. D. Rueda, I. Galve-Roperh, A. Haro, and M. Guzman, “The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase,” Molecular Pharmacology, vol. 58, no. 4, pp. 814–820, 2000.
  44. L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “Kinase signaling cascades that modulate peroxisome proliferator-activated receptors,” Current Opinion in Cell Biology, vol. 17, no. 2, pp. 216–222, 2005. View at Publisher · View at Google Scholar · View at PubMed
  45. R. G. Pertwee, “The pharmacology of cannabinoid receptors and their ligands: an overview,” International Journal of Obesity, vol. 30, suppl. 1, pp. S13–S18, 2006. View at Publisher · View at Google Scholar · View at PubMed